Galera Therapeutics, Inc.

What they do

Galera historically developed small molecule superoxide dismutase mimetics to reduce severe oral mucositis from radiotherapy; in October 2025 it sold avasopasem, rucosopasem and all other dismutase mimetic assets to Biossil, Inc. The company's remaining portfolio is a pan-nitric oxide synthase (NOS) inhibitor acquired with Nova Pharmaceuticals in December 2024, aimed at metaplastic breast cancer (MpBC) and refractory triple-negative breast cancer (TNBC). Its lead program is an investigator-sponsored Phase 1/2 trial of the pan-NOS inhibitor with nab-paclitaxel and alpelisib, funded by an NIH grant to Houston Methodist. The company reported 3 employees as of December 31, 2025.

Revenue drivers

• Biossil asset sale consideration — Galera received a $3.5 million upfront payment from Biossil in October 2025 and is eligible for future regulatory and commercial milestone payments plus contingent value rights of up to $105.0 million in the aggregate.
• Pan-NOS inhibitor program — The lead product candidate is in an investigator-sponsored Phase 1/2 trial in MpBC, funded by an NIH grant including drug supply; the company has no product revenue and plans a second TNBC trial with the I-SPY 2 consortium if it secures capital.
• Obsidian merger and Series C financing — In April 2026 Galera agreed to be acquired by Obsidian Therapeutics and separately agreed to sell Series C Non-Voting Convertible Preferred Stock for aggregate gross proceeds of approximately $350.0 million, less any proceeds received by Obsidian.

Recent performance

Galera reported net income of $149.0 million for 2025, primarily due to a $151.0 million non-cash gain from derecognition of the Blackstone royalty purchase liability after Biossil assumed the Royalty Agreement, compared to a net loss of $19.0 million in 2024. Diluted EPS was $0.64 in 2025 versus negative $0.34 in 2024, and operating cash flow improved to negative $6.0 million in 2025 from negative $12.1 million in 2024. As of December 31, 2025, Galera had $6.4 million in cash and cash equivalents and an accumulated deficit of $307.3 million. On the latest balance sheet dated March 31, 2026, total assets were $6.2 million, total liabilities $1.1 million, shareholder equity $728,000, and cash and equivalents $5.5 million.

Strategy

Galera's stated strategy is to develop its pan-NOS inhibitor for advanced breast cancer, including MpBC and other refractory TNBC subsets, through investigator-sponsored trials. The lead Phase 1/2 trial combining the pan-NOS inhibitor with nab-paclitaxel and alpelisib is funded by an NIH grant to Houston Methodist, including drug supply, and the Phase 2a portion was reached in 2025 with two additional sites added: MD Anderson and the NIH Clinical Center. Assuming additional capital, Galera plans a second trial in TNBC with the I-SPY 2 consortium. In April 2026, Galera entered a merger agreement with Obsidian Therapeutics under which the combined company would operate as Obsidian Therapeutics, Inc. and focus primarily on advancing Obsidian's engineered TIL cell therapies, including OBX-115, while continuing to support Galera's pipeline. Galera also continues to consider partnerships and alternative ways to advance its indications.

Risks

• Going concern and capital needs — Galera had $5.5 million in cash and equivalents as of March 31, 2026 and management stated that cash as of December 31, 2025 was anticipated to fund operations only through the first quarter of 2027.
• Merger closing uncertainty — The April 2026 Obsidian merger is subject to stockholder approvals, SEC registration effectiveness and other customary conditions, so it may not close on the contemplated terms or at all.
• Single early-stage asset — After the Biossil sale, Galera's portfolio is one pan-NOS inhibitor in Phase 1/2 testing, so program failure or delay would leave the company without other product candidates.
• Dependence on external parties — The lead trial is investigator-sponsored and NIH-funded at Houston Methodist with drug supply provided by the grant, meaning Galera does not control enrollment, timelines or supply.

Outlook

Management expects to continue incurring significant expenses and operating losses for the foreseeable future, and expects existing cash and cash equivalents as of December 31, 2025 to fund operating expenses and capital expenditure requirements for at least twelve months from the filing of the 2025 Form 10-K. Future capital requirements depend on strategic alternatives, and the company anticipates a second TNBC trial in collaboration with the I-SPY 2 consortium only if it secures additional capital. The combined company with Obsidian is expected to operate as Obsidian Therapeutics, Inc. and focus primarily on Obsidian's TIL cell therapies, including OBX-115, while continuing to support Galera's pipeline.